ACCURAY INCARAYEarnings & Financial Report
Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare ...
ARAY Q2 FY2026 Key Financial Metrics
Revenue
$102.2M
Gross Profit
$24.1M
Operating Profit
$-11.6M
Net Profit
$-13.8M
Gross Margin
23.5%
Operating Margin
-11.3%
Net Margin
-13.5%
YoY Growth
-12.0%
EPS
$-0.11
ACCURAY INC Q2 FY2026 Financial Summary
ACCURAY INC reported revenue of $102.2M (down 12.0% YoY) for Q2 FY2026, with a net profit of $-13.8M (down 642.8% YoY) (-13.5% margin). Cost of goods sold was $78.2M, operating expenses totaled $35.6M.
Key Financial Metrics
| Total Revenue | $102.2M |
|---|---|
| Net Profit | $-13.8M |
| Gross Margin | 23.5% |
| Operating Margin | -11.3% |
| Report Period | Q2 FY2026 |
Revenue Breakdown
ACCURAY INC Q2 FY2026 revenue of $102.2M breaks down across 2 segments, led by Services at $57.2M (56.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Services | $57.2M | 56.0% |
| Products | $45.0M | 44.0% |
ACCURAY INC Revenue by Segment — Quarterly Trend
ACCURAY INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and Products) has evolved quarter over quarter.
| Segment | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Services | $57.2M | $56.8M | $56.8M | $55.9M |
| Products | $45.0M | $37.2M | $70.7M | $57.3M |
ACCURAY INC Annual Revenue by Year
ACCURAY INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $458.5M).
ACCURAY INC Quarterly Revenue & Net Profit History
ACCURAY INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $102.2M | -12.0% | $-13.8M | -13.5% |
| Q1 FY2026 | $93.9M | -7.5% | $-21.7M | -23.1% |
| Q4 FY2025 | $127.5M | -5.0% | $1.1M | 0.9% |
| Q3 FY2025 | $113.2M | +12.0% | $-1.3M | -1.1% |
| Q2 FY2025 | $116.2M | +8.3% | $2.5M | 2.2% |
| Q1 FY2025 | $101.5M | -2.3% | $-4.0M | -3.9% |
| Q4 FY2024 | $134.3M | +13.5% | $3.4M | 2.5% |
| Q3 FY2024 | $101.1M | -14.3% | $-6.3M | -6.3% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $101.1M | $134.3M | $101.5M | $116.2M | $113.2M | $127.5M | $93.9M | $102.2M |
| YoY Growth | -14.3% | 13.5% | -2.3% | 8.3% | 12.0% | -5.0% | -7.5% | -12.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $462.5M | $468.6M | $473.1M | $478.4M | $484.3M | $470.2M | $456.8M | $448.0M |
| Liabilities | $421.4M | $423.5M | $427.9M | $430.5M | $434.7M | $389.1M | $394.9M | $394.6M |
| Equity | $41.1M | $45.1M | $45.2M | $47.9M | $49.6M | $81.2M | $61.9M | $53.4M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.1M | $9.9M | $-7.3M | $1.8M | $18.1M | $-9.7M | $12.2M | $-16.0M |